KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Equity Income (2018 - 2020)

Historic Equity Income for Arbutus Biopharma (ABUS) over the last 3 years, with Q3 2020 value amounting to -$2.5 million.

  • Arbutus Biopharma's Equity Income rose 2753.42% to -$2.5 million in Q3 2020 from the same period last year, while for Dec 2021 it was -$2.5 million, marking a year-over-year change of 0.0%. This contributed to the annual value of -$2.5 million for FY2020, which is 8869.99% up from last year.
  • Per Arbutus Biopharma's latest filing, its Equity Income stood at -$2.5 million for Q3 2020, which was up 2753.42% from -$11.0 million recorded in Q4 2019.
  • Arbutus Biopharma's 5-year Equity Income high stood at -$2.5 million for Q3 2020, and its period low was -$11.0 million during Q4 2019.
  • In the last 3 years, Arbutus Biopharma's Equity Income had a median value of -$3.3 million in 2019 and averaged -$4.4 million.
  • Per our database at Business Quant, Arbutus Biopharma's Equity Income tumbled by 30473.57% in 2019 and then surged by 2753.42% in 2020.
  • Quarter analysis of 3 years shows Arbutus Biopharma's Equity Income stood at -$2.7 million in 2018, then plummeted by 304.74% to -$11.0 million in 2019, then soared by 76.92% to -$2.5 million in 2020.
  • Its last three reported values are -$2.5 million in Q3 2020, -$11.0 million for Q4 2019, and -$3.5 million during Q3 2019.